Literature DB >> 2476401

Antigenic variation within serotypes of Cryptococcus neoformans detected by monoclonal antibodies specific for the capsular polysaccharide.

C Spiropulu1, R A Eppard, E Otteson, T R Kozel.   

Abstract

The serotype-specific polysaccharide was isolated from four to seven strains of each of the four major serotypes of Cryptococcus neoformans. Reactivities of polysaccharides with seven monoclonal antibodies raised against polysaccharides of serotypes A, B, C, and D were assessed by an enzyme-linked immunosorbent assay and double immunodiffusion. The results indicated that there is heterogeneity within all four serotypes in the expression of epitopes reactive with monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476401      PMCID: PMC260798          DOI: 10.1128/iai.57.10.3240-3242.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  9 in total

1.  Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.

Authors:  T F Eckert; T R Kozel
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

2.  Serologic grouping of Cryptococcus neoformans.

Authors:  D E Wilson; J E Bennett; J W Bailey
Journal:  Proc Soc Exp Biol Med       Date:  1968-03

3.  Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A.

Authors:  R Cherniak; E Reiss; M E Slodki; R D Plattner; S O Blumer
Journal:  Mol Immunol       Date:  1980-08       Impact factor: 4.407

4.  Capsular polysaccharides from a parent strain and from a possible, mutant strain of Cryptococcus neoformans serotype A.

Authors:  A K Bhattacharjee; K J Kwon-Chung; C P Glaudemans
Journal:  Carbohydr Res       Date:  1981-09-16       Impact factor: 2.104

5.  Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C).

Authors:  K J Kwon-Chung; I Polacheck; J E Bennett
Journal:  J Clin Microbiol       Date:  1982-03       Impact factor: 5.948

6.  Chemical characterization of capsular polysaccharide from Cryptococcus neoformans serotype A-D.

Authors:  R Ikeda; A Nishikawa; T Shinoda; Y Fukazawa
Journal:  Microbiol Immunol       Date:  1985       Impact factor: 1.955

7.  Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates.

Authors:  R Ikeda; T Shinoda; Y Fukazawa; L Kaufman
Journal:  J Clin Microbiol       Date:  1982-07       Impact factor: 5.948

8.  Structure determination of Cryptococcus neoformans serotype A-variant glucuronoxylomannan by 13C-n.m.r. spectroscopy.

Authors:  R Cherniak; R G Jones; E Reiss
Journal:  Carbohydr Res       Date:  1988-01-15       Impact factor: 2.104

9.  Structural studies on the major, capsular polysaccharide from Cryptococcus bacillisporus serotype B.

Authors:  A K Bhattacharjee; K J Kwon-Chung; C P Glaudemans
Journal:  Carbohydr Res       Date:  1980-06       Impact factor: 2.104

  9 in total
  36 in total

1.  In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans.

Authors:  K Truelsen; T Young; T R Kozel
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

2.  Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans.

Authors:  Ryan M Kelly; Jianmin Chen; Lauren E Yauch; Stuart M Levitz
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

3.  In vivo role of dendritic cells in a murine model of pulmonary cryptococcosis.

Authors:  Karen L Wozniak; Jatin M Vyas; Stuart M Levitz
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.

Authors:  Marcellene A Gates-Hollingsworth; Thomas R Kozel
Journal:  Mol Microbiol       Date:  2009-09-02       Impact factor: 3.501

5.  Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.

Authors:  G Nussbaum; S Anandasabapathy; J Mukherjee; M Fan; A Casadevall; M D Scharff
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

6.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

7.  Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay.

Authors:  T Belay; R Cherniak; T Shinoda
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

8.  Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.

Authors:  J Mukherjee; M D Scharff; A Casadevall
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides.

Authors:  J Stacey Klutts; Tamara L Doering
Journal:  J Biol Chem       Date:  2008-03-17       Impact factor: 5.157

10.  Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components.

Authors:  Karen L Wozniak; Stuart M Levitz
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.